Jane Street Group LLC Purchases Shares of 35,731 Nabriva Therapeutics plc – (NASDAQ:NBRV)

Jane Street Group LLC bought a new position in shares of Nabriva Therapeutics plc – (NASDAQ:NBRV) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 35,731 shares of the biotechnology company’s stock, valued at approximately $293,000. Jane Street Group LLC owned approximately 0.10% of Nabriva Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of NBRV. Almanack Investment Partners LLC. increased its position in Nabriva Therapeutics by 482.2% in the 2nd quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after acquiring an additional 751,366 shares during the period. Alyeska Investment Group L.P. acquired a new position in Nabriva Therapeutics in the 3rd quarter valued at about $5,724,000. Commonwealth Equity Services Inc increased its position in Nabriva Therapeutics by 109.7% in the 3rd quarter. Commonwealth Equity Services Inc now owns 26,760 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 14,000 shares during the period. Royal Bank of Canada increased its position in Nabriva Therapeutics by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after acquiring an additional 8,650 shares during the period. Finally, Nationwide Fund Advisors increased its position in Nabriva Therapeutics by 4.6% in the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after acquiring an additional 7,924 shares during the period. Institutional investors and hedge funds own 57.12% of the company’s stock.

Several brokerages recently issued reports on NBRV. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Nabriva Therapeutics in a research report on Tuesday, September 19th. Leerink Swann restated an “outperform” rating and issued a $22.00 price target (up previously from $20.00) on shares of Nabriva Therapeutics in a research report on Monday, September 18th. Cantor Fitzgerald restated a “buy” rating and issued a $16.00 price target on shares of Nabriva Therapeutics in a research report on Monday, September 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price objective (up previously from $15.00) on shares of Nabriva Therapeutics in a report on Tuesday, September 19th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $21.00 price objective (up previously from $13.00) on shares of Nabriva Therapeutics in a report on Monday, September 18th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $18.61.

Shares of Nabriva Therapeutics plc – (NASDAQ NBRV) traded down $0.03 on Friday, reaching $6.18. The company’s stock had a trading volume of 74,222 shares, compared to its average volume of 263,298. Nabriva Therapeutics plc – has a 12 month low of $4.75 and a 12 month high of $14.10. The stock has a market cap of $227.85 and a price-to-earnings ratio of -0.24.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/13/jane-street-group-llc-purchases-new-holdings-in-nabriva-therapeutics-plc-nbrv-updated-updated.html.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Institutional Ownership by Quarter for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply